key: cord-0837937-lhoezgcq authors: Palich, R.; Wakim, Y.; Itani, O.; Paccoud, O.; Boussouar, S.; Lévy-Soussan, M.; Soulie, C.; Godefroy, N.; Bleibtreu, A. title: Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients date: 2021-01-18 journal: Infect Dis Now DOI: 10.1016/j.idnow.2020.12.004 sha: 48eb958c02fb88705871eae61cf280c238fd5b40 doc_id: 837937 cord_uid: lhoezgcq Objective: To describe clinical, biological, radiological presentation and W4 status in COVID-19 elderly patients. Patients and methods: All patients ≥70 years with confirmed SARS-CoV-2 infection and hospitalized in the Infectious Diseases department of the Pitié-Salpêtrière hospital, Paris, France, from March 1st to April 15th 2020 were included. The primary outcome was death four weeks after hospital admission. Data on demographics, clinical features, laboratory tests, CT-scan findings, therapeutic management and complications were collected. Results: All in all, 100 patients were analyzed, including 49 patients ≥80 years. Seventy percent had ≥2 comorbidities. Respiratory features were often severe as 48% needed oxygen support upon admission. Twenty-eight out of 43 patients (65%) with a CT-scan had mild to severe parenchymal impairment, and 38/43 (88%) had bilateral impairment. Thirty-two patients presented respiratory distress requiring oxygen support ≥6 liters/minute. Twenty-four deaths occurred, including 21 during hospitalization in our unit, 2 among the 8 patients transferred to ICU, and one at home after discharge from hospital, leading to a global mortality rate of 24% at W4. Age, acute renal failure and respiratory distress were associated with mortality at W4. Conclusion: A substantial proportion of elderly COVID-19 patients with several comorbidities and severe clinical features survived, a finding that could provide arguments against transferring the most fragile patients to ICU. COVID-19 is an infection having to do with the novel coronavirus SARS-CoV-2 [1] . It started spreading from Wuhan, China in December 2019, leading to a major pandemic. By early September 2020, nearly 27 million COVID-19 cases were reported worldwide, associated with 900,000 deaths [2] . In France, almost 300,500 cases and 30,500 deaths have been documented since February 2020 [3] . Elderly population bear a heavy burden, with fatality rates reaching 26% and 58% in patients aged over 70 and 80 years, respectively. Most cohort studies have found age to be the main risk factor for mortality [4] [5] [6] . On May 12 th in France, persons over 75 years of age represented 56% of inpatients, 71% of deaths having occurred during hospital stay, and only 19% of patients admitted in ICU [3] . Elderly COVID-19 patients consequently represent a high proportion of inpatients in medical wards. Despite frequent severe respiratory forms and accumulation of risk factors, a substantial number of these patients survive the infection. However, data in this population are very limited, especially among survivors after discharge from hospital. Herein, we aimed to describe clinical, biological and radiological presentation of COVID-19 in patients over 70 years of age, in the Infectious and Tropical Diseases department of the Pitié-Salpêtrière University hospital (Paris, France), as well as clinical outcome 4 weeks (W4) after admission and the factors associated with mortality. We performed a retrospective, single-center study in the Infectious and Tropical Diseases department at the Pitié-Salpêtrière University Hospital, Paris, France. We included all confirmed cases of COVID-19 in patients over 70 years old admitted from March 1 st to April The primary outcome was vital status (survival or death) 4 weeks after hospital admission. The secondary outcomes were length of hospital stay, occurrence of acute respiratory distress and/or other complications during clinical course, transfer to ICU, "do not resuscitate" order, use of hypnotic and opioid drugs, place of residence (at home or retirement home, subacute care ward, ICU) 4 weeks after hospital admission for survivors, and factors associated with vital status at week 4 (W4). We obtained data retrospectively from electronic medical records, which were carefully reviewed by three trained physicians. Patient data included demographics, home medications, comorbidities, initial signs and symptoms, onset of signs and symptoms, triage vital signs, initial laboratory tests, value of cycle threshold (Ct) for SARS-CoV-2 RT-PCR, chest computed tomographic scan results, treatments received during hospitalization (antivirals, antibiotics, corticosteroids and oxygen support), maximum body temperature, and length of hospital stay. The Charlson index was used to evaluate patients' medical state before admission [7] . The NEWS-2 score was used to standardize assessment of acute-illness severity at admission [8] . The occurrence of acute respiratory distress during clinical course was defined as the recourse to oxygen support ≥6 liters/minute to maintain blood oxygen saturation (SpO2) ≥94%. We also collected other significant complications (acute renal injury, Nasopharyngeal swab and sputum samples were collected and tested by RT-PCR with the Cobas® SARS-CoV-2 kit (Roche), as recommended by the manufacturer, after neutralization with an equal amount of Cobas lysis buffer for SARS-CoV-2 (400/400 µL). Three categories of Ct were retained: Ct<20 (high SARS-CoV-2 viral load), 20 30 (low viral load). All scans were performed on a dedicated scanner (Siemens Somaton Edge) either without iodine injection or after IV of 60 mL iodinated contrast agent (Iomeprol 400 Mg I/mL, Bracco Imaging, Milan, IT) in cases of suspected pulmonary embolism. A radiologist (SB), who was blinded to clinical and biological features including RT-PCR results, reviewed all chest CT images on a PACS workstation (Carestream Health, Rochester, NY) and classified the chest CT as positive or negative for COVID-19 according to previously described CT features [9] [10] [11] . The radiologist also described the main CT features (ground-glass opacity, consolidation, reticulation/thickened interlobular septa, nodules, emphysema, pleural effusion), and lesion distribution (left, right or bilateral lungs). A semi-quantitative score was assigned (0% involvement; less than 25%; 25% to less than 50%; 50% to less than 75%; 75% or greater). All images were viewed on both lung and mediastinal settings. For each patient we reported whether a transfer to ICU had been considered during clinical course, whether a "do not resuscitate" order had been collectively decided, and whether hypnotic or opioid drugs were used. Patients or family were contacted by a physician four weeks after admission to collect vital status and place of residence at W4. common accompanying diseases including emphysema (n=9), bronchiectasis (n=1), and pleural sequelae (n=1). Associated pulmonary oedema was detected in one patient. CT scan injections were administered in 42% of cases, with no pulmonary embolism detected. Sixty-five patients received antibiotics, including a beta-lactam in 97% of cases and/or a macrolide in 98% of cases (Table 3) . Thirty percent of patients received hydroxychloroquine for a median duration of 9 days (IQR 2-10). No cardiac side effects were observed in patients treated by hydroxychloroquine. Seven percent of patients received short-term corticosteroid therapy (2-5 days). Thirty-two patients presented clinical deterioration with respiratory distress requiring oxygen support ≥6 liters/minute. Respiratory distress occurred after a median time of 10 days (IQR 4-13) after the onset of symptoms. Among these 32 patients, 8 (25%) were transferred to ICU ( Figure 1 ). All were <80 years. For the 24 others, a "do not resuscitate" order was decided on. Hypnotic and opioid drugs were used in 17 cases. All in all, 24 deaths occurred from hospital admission to W4, including 21 deaths during hospitalization in our unit, 2 deaths in ICU and one death at home after discharge from hospital, leading to a global mortality rate of 24% at W4 (Figure 2a All in all, among surviving patients, 46/67 (69%) had returned home or to their institution and 21/67 (31%) were still hospitalized in a subacute care ward. The older the patient's age, the greater the risk of dying (OR 1.15, 95%CI 1.05-1.27, p=0.005); in other words, 10 more years equated to 15% more risk of dying due to COVID-19. The occurrence of respiratory distress was also associated with death (OR 6.53, 95%CI 1.20-45.6, p=0.038). Interestingly, 13 patients survived despite acute respiratory distress, without mechanical ventilation and after having received sustained oxygen support (6, 9 and 15 liters/minute for 4, 3 and 6 patients, respectively). Aside from age and respiratory distress, only acute renal failure at admission was strongly associated with mortality at W4 (OR 73.8, 95%CI 5.7-3721.2, p=0.006). In our study, patients aged ≥65 years with COVID-19 presented severe clinical course and frequently required respiratory support. The high mortality rate (24%) is consistent with similar findings in other countries such as China, Korea or the USA [12] [13] [14] . In a recent cohort study conducted in French acute care geriatric wards, the mortality rate was higher (31%), probably due to higher median age (86 vs. 79 years in our population) and poorer general health conditions (29% lived in an institution vs. 11% in our population) [15] . included several very old patients (half of them were ≥80 years), 76% of patients survived during their hospital stay. Moreover, 70% of our patients received hospital admission prior to D7, i.e. before theorical deterioration of their clinical condition. This survival rate is all the more interesting insofar as some patients were temporarily in critical condition (n=13), and a few were transferred to ICU (n=8). Viral pneumonia is one of the most frequent complications of COVID-19, requiring oxygen therapy and endotracheal intubation for the most severe forms [16] . Intensive care unit (ICU) stays are often extended for several weeks and burdened with high mortality rates, especially among older patients [17, 18] In many centers, access to ICU for patients over 70 years old is highly restricted, due to the poor prognosis [19] . In our study, no ICU transfer was decided for patients ≥80 years. More generally, up until now reported mortality rates in ICU in this population have ranged from 40 to 80%, although more robust data on short-and long-term outcomes are needed [17, 20] . In our establishment, oxygen support is performed by nasal canula, simple mask, or non-rebreathing mask. We were unable to use very high flow oxygen therapy (Optiflow system) or non-invasive ventilation, which could have represented alternatives to endo-tracheal intubation while enhancing survival. In order to assess delayed mortality in elderly patients with COVID-19, we systematically contacted discharged patients or their families 4 weeks after their admission in our department. Prior to analysis, we expected non-negligible mortality at discharge due to sequalae of the disease and loss of autonomy, but in only one patient were we able to authenticate death after discharge, a finding seeming to suggest satisfactory recovery after the disease. However, and in spite of full pre-admission autonomy, a significant proportion of our patients were still hospitalized in subacute care wards, suggesting a slow return to health 12 baseline. Moreover, we could not positively exclude the death of the 8 lost to follow-up patients. As in previous cohorts, the most frequent symptoms associated with SARS-CoV-2 infection were fever, cough and dyspnea [17, 21] . However, isolated symptoms such as digestive disorders and confusion were not rare (16% and 14%, respectively, in our population), a finding highlighting the extent to which elderly patients are likely to require special attention [22] . Radiological presentations were consistent with clinical presentations, showing frequent signs of severe parenchymal impairment. Previous works have shown that pulmonary lesions are more extensive and more often bilateral in elderly patients than in younger patients [23, 24] . Surprisingly, no pulmonary embolism was detected, while venous thromboembolic disease may reach 20% during COVID-19 course in hospitalized patients [25] . The number of patients receiving an anticoagulant treatment before the infection (23%) could partially explain this result. Antibiotics were widely used, and certainly over-used, due to inadequate knowledge at the onset of the pandemic outbreak. We treated patients using MERS-CoV-2 management as a model [26] . That said, no antibiotic side effects were reported (no allergic reactions, Several comorbidities (cardiovascular and lung diseases, diabetes, dementia or cancer), all of which increase with age, may have been present [30] . We investigated whether clinical and biological characteristics were associated with death. In our population, age and respiratory distress were significantly associated with mortality at W4, results that matched the prognostic factors found in other studies [6, 15, 31, 32] . Acute renal failure at hospital admission was likewise associated with mortality. Other works have observed renal impairment in some severe forms of COVID-19, and it may represent an independent factor associated with mortality [33, 34] . While several other factors such as severe initial clinical presentation (reflected by the NEWS-2 score) or biological abnormalities have been reported to be poor prognostic factors [6, 15, 31, 32] , this was not the case in our population. We assume that the characteristics of our patient sample were too homogeneous to detect significant differences according to final outcome. Indeed, all patients were hospitalized in the same medical unit, almost all had a significant number of comorbidities as medical background, and almost all were suffering from severe SARS-CoV-2 infection. This study has several limitations. First, it was a retrospective study with a relatively small number of patients and some unavailable biological data, limiting the field of our analysis with possible confounding factors. Second, our study subjects consisted of hospitalized patients; those deemed sufficiently fit for home isolation were not included, which could explain the high mortality and severity observed. Therefore, our results are not generalizable to mild cases. Finally, we did not use standardized geriatric scales (i.e. ADL, IALD) to accurately assess the overall progress of our elderly patients. of Novel Coronavirus-Infected Pneumonia COVID-19 weekly surveillance report, data for the week of COVID-19 French national and regional weekly review Disparities in Age-Specific Morbidity and Mortality from SARS-CoV-2 in China and the Republic of Korea Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19) Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up Risk Factors for Mortality and Respiratory Support in Elderly Patients Hospitalized with COVID-19 in Korea COVID-19) -United States Clinical Characteristics and Outcomes of 821 Older Patients with SARS-Cov-2 Infection Admitted to Acute Care Geriatric Wards Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Should we deny ICU admission to the elderly? Ethical considerations in times of COVID-19 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications Clinical and CT findings of COVID-19: differences among three age groups Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients Pulmonary embolism in patients with COVID-19 pneumonia Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital Rapid Evidence Appraisal for COVID-19 Therapies Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study Kidney disease is associated with in-hospital death of patients with COVID-19 Is the kidney a target of SARS-CoV-2?